Treatment for Waldenstrom's macroglobulinemia.
Waldenstrom's macroglobulinemia is a rare form of indolent lymphoma characterized by the production of a monoclonal immunoglobulin M protein, and complications such as hyperviscosity, cytopenias and peripheral neuropathy. Conventional treatment approaches are based on alkylators or nucleoside analogs, but in the absence of a clearly superior regimen, a broad array of alternative therapies exists. Choices range from biological agents to combination chemotherapy to stem-cell transplantation. A rational approach therefore must be based on careful patient assessment and individualization of therapy.
Chen
C I
CI
Princess Margaret Hospital/Ontario Cancer Institute, Toronto, Ontario, Canada. Christine.chen@uhn.on.ca
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D009705:Nucleosides / Q000819:agonists; D011379:Prognosis; D033581:Stem Cell Transplantation; D013997:Time Factors; D008258:Waldenstrom Macroglobulinemia / Q000628:therapy*
D018906:Antineoplastic Agents, Alkylating; D009705:Nucleosides